In leukemia cells, the treatment with venetoclax (BCL2 inhibitor) impacts the tricarboxylic acid by inhibiting amino acid metabolism and contributing to the selective elimination of this cell population [10,11,12]. The gene discussed is BCL2; the disease is leukemia.